Veeva Systems (VEEV)
(Delayed Data from NYSE)
$209.43 USD
+4.30 (2.10%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $209.36 -0.07 (-0.03%) 5:42 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$209.43 USD
+4.30 (2.10%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $209.36 -0.07 (-0.03%) 5:42 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Zacks News
3 Reasons to Add AMN Healthcare (AMN) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about AMN Healthcare (AMN) due to its broad array of services and strength in staffing service.
Reasons to Add West Pharmaceutical (WST) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about West Pharmaceutical (WST) due to its solid proprietary products segment.
Abbott (ABT) CE-Marked Panbio Test Now Widely Offered in Europe
by Zacks Equity Research
Abbott's (ABT) Panbio COVID-19 Antigen Self-Test is expected to facilitate mass screenings and aid in resumption of daily life activities with the gradual reopening of economies worldwide.
Abiomed's (ABMD) Impella RP With SmartAssist Gets FDA Nod
by Zacks Equity Research
Abiomed's (ABMD) Impella RP with SmartAssist gets the highest level of approval from the FDA for treatment of right heart failure.
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio. However, segmental weakness is a woe.
Here's Why You Should Retain Catalent (CTLT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Catalent (CTLT) owing to its slew of strategic deals, and integrated development and product supply chain solutions.
Pacific Biosciences (PACB)-RCIGM Tie Up for Sequencing Research
by Zacks Equity Research
Pacific Biosciences' (PACB) latest research tie-up is likely to use HiFi Sequencing data on some of the most difficult cases of rare pediatric disease and provide insights into the treatment journey.
Here's Why You Should Retain Ecolab (ECL) Stock Right Now
by Zacks Equity Research
Ecolab (ECL) continues to gain traction for a solid product portfolio and cost-efficiency program. However, segmental weakness remains a woe.
Fresenius Medical's (FMS) Training Center to Boost Patient Care
by Zacks Equity Research
Fresenius Medical (FMS) inaugurates new training center in Korea to help in the improvement of patient care by offering comprehensive education programs for healthcare professionals.
Catalent (CTLT) to Enhance Its Portfolio via RheinCell Buyout
by Zacks Equity Research
Catalent (CTLT) expects to strengthen its position in new therapeutic areas and boost its cell therapy portfolio via the latest acquisition.
Moving Average Crossover Alert: Veeva Systems (VEEV)
by Zacks Equity Research
Veeva Systems (VEEV) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Allscripts' (MDRX) Unit Inks Deal to Boost Clinical Research
by Zacks Equity Research
Allscripts' (MDRX) unit, Veradigm, enters into a strategic partnership with PRA Health (PRAH) to expand patients' access to clinical research.
BD's (BDX) PeritX System Gets FDA's Expanded 510(k) Clearance
by Zacks Equity Research
BD's (BDX) receipt of the expanded FDA indication for its PeritX System is expected to lessen the number of hospital trips a patient takes for fluid removal.
Here's Why You Should Add Inogen (INGN) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Inogen (INGN) on its direct-to-customer business model and a strong product portfolio.
Here's Why You Should Retain Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform - Mako and broad product portfolio. However, pricing pressure raises a concern.
Patterson Companies (PDCO) Q4 Earnings Miss, Revenues Beat
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal fourth-quarter 2021 results benefit from strong segmental performance.
PerkinElmer (PKI) to Boost Portfolio via SIRION Acquisition
by Zacks Equity Research
PerkinElmer (PKI) expects to be able to support its cell and gene therapy workflows, and expand its existing research solutions via the latest buyout.
AngioDynamics (ANGO) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
AngioDynamics (ANGO) is optimistic about maintaining its robust product portfolio.
Masimo's (MASI) Wearable Wireless Thermometer Gets FDA Nod
by Zacks Equity Research
Masimo's (MASI) continuous, wearable thermometer is likely to help monitor and track body temperature in all thermometer applications following the FDA's clearance.
NextGen (NXGN) Partners With Palmetto to Boost Patient Experience
by Zacks Equity Research
NextGen (NXGN) collaborates with Palmetto to enhance patient experience, through the latter's adoption of NextGen RCM Services.
OPKO Health (OPK) Inks Agreement to Sell Its Ireland Facility
by Zacks Equity Research
OPKO Health (OPK) expects to improve its business efficacy and focus on oral solid dose products post the sale of its Ireland facility.
What's in Store for Patterson Companies' (PDCO) Q4 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal fourth-quarter results are likely to reflect improvement at Dental segment.
Here's Why You Should Retain Integer Holdings (ITGR) Stock
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from portfolio management.
Here's Why You Should Add DaVita (DVA) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about DaVita (DVA) on its slew of tie-ups and strength in its kidney care business.
Cybersecurity Gains Prominence in Healthcare: 3 Stocks to Watch
by Trina Mukherjee
Here we look at three stocks, VEEV, HSIC and BDX, that investors can keep a watch on the back of their robust cybersecurity measures.